Vanguard Capital Management
TLSI icon

Vanguard Capital Management’s TriSalus Life Sciences TLSI Stock Holding History

Vanguard Capital Management’s Portfolio TLSI Stock Details TLSI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.42M Sell
1,720,671
-8,714
-0.5% -$41.3K ﹤0.01% 2938
2026
Q2 		$7.87M Buy
1,729,385
+382,349
+28% +$1.52M ﹤0.01% 2949
2026
Q1 		$5.39M Buy
+1,347,036
New +$6.6M ﹤0.01% 3033

Other funds holding TLSI

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $87.3B AUM 22.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Kennedy Capital Management
Kennedy Capital Management St Louis, Missouri $5.31B AUM 40.5% 1-Year Est. Return
Thompson Siegel & Walmsley
Thompson Siegel & Walmsley Richmond, Virginia $5.37B AUM 3.99% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return
White Pine Capital
White Pine Capital Bloomington, Minnesota $419M AUM 48.71% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return

Vanguard Capital Management's TLSI Position: Q3 2026 in Review

Vanguard Capital Management reduced its TriSalus Life Sciences (TLSI) stake by 0.5% in Q3 2026, selling an estimated $41.3K and leaving 1,720,671 shares worth $7.42M. The position accounts for ﹤0.01% of the portfolio, ranked #2938.

Vanguard Capital Management first reported a position in TLSI in Q1 2026 and has held it in 3 quarters since. The position peaked at $7.87M in Q2 2026. 58 funds tracked by Wall St. Rank hold TLSI as of Q3 2026.

  • Vanguard Capital Management held 1,720,671 shares of TriSalus Life Sciences worth $7.42M as of Q3 2026.
  • Vanguard Capital Management sold 8,714 TriSalus Life Sciences shares in Q3 2026, an estimated $41.3K.
  • TriSalus Life Sciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2938 holding.
  • Vanguard Capital Management first reported a position in TriSalus Life Sciences in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's TriSalus Life Sciences position peaked at $7.87M in Q2 2026.
  • 58 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.